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Summary. HSP27 belongs to the Heat shock protein
(HSP) family, which plays essential functions in cells
under physiological conditions and prevents stress-
induced cellular damage. The aim of this study was to
investigate the biological role of HSP27 in oral
tumorigenesis. Materials and methods: Seventy-nine
cases of oral squamous cell carcinoma and 10 cases of
normal mucosa were analysed for HSP27 expression by
immunohistochemistry. Moreover, the western blot
analysis was performed on two cases of normal mucosa
and five cases of OSCC. Results: Normal oral mucosa
showed a suprabasal expression of HSP27. Twenty-four
cases of SCC (30.7%) showed a diffuse staining for
HSP27, and 48 cases (60.3%) showed instead a decrease
in staining, which was diffuse, homogeneous, or with
alternation of positive and negative areas in a single
tumor (“mosaic” pattern). Only 7 cases of OSCC (7.5%)
were completely negative for HSP27. Frequency of
lymph node metastases was higher in HSP27-negative
tumours (3/7, 42.8%) than in HSP-reduced (16/48,
33.3%) or positive ones (5/26, 19.2%). Regard staging,
stages I and II had a higher score than stages III and IV
(stage I > stage II > stage III > stage IV). There was also
a statistically significant correlation between HSP27
expression and grade: HSP27 expression was reduced in
poorly differentiated tumours (P < 0.05). When analysed
for prognostic significance, patients with
negative/reduced HSP27 expression had poorer survival
rates than the group with positive HSP27 expression (P
< 0.05). The statistical analysis of these findings showed
no significant correlation between HSP27 expression,
sex, and tumour size. Conclusion: Cases with reduced
expression were more aggressive and poorly
differentiated. These data suggest that HSP27 expression
may be useful in order to identify cases of oral squamous
cell carcinoma with more aggressive and invasive
phenotype providing novel diagnostic and prognostic
information on individual patient survival with oral
cancers.
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Introduction
Heat shock protein (HSP) family is a large family
which plays essential homeostatic functions in cells
under physiological conditions and in protecting cells
against damage in stressful conditions. On the basis of
their molecular weights HSPs have been grouped into
different sub-families: small (HSP 20-30-KDa), HSP40,
HSP60, HSP70, HSP90 and HSP100. Intracellulary,
HSPs, the most conserved proteins throughout evolution
(Lindquist and Craig, 1988), are involved in several
processes such as protein denaturation-renaturation,
folding-unfolding, transport-translocation, activation-
inactivation, and secretion (Frydman et al., 
1994). 
Experimental evidence suggests that HSPs may
promote tumorigenesis by suppressing apoptosis
(Jaattela, 1999). On the contrary, it seems that some
members of HSPs play important roles in the immune
response against cancer (Multhoff et al., 1997). 
HSP27 is a cytoplasmic protein that is constitutively
expressed in a broad range of normal tissues and
neoplasms. HSP27 is constitutively expressed at low
levels in most human tissues (Lindquist and Craig,
1988). After induction, the protein becomes
phosphorylated and simultaneously translocated from
the cytoplasm to within or around the nucleus (Lavoie et
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al., 1993). The phosphorylation process is a key
regulator of HSP27 functions: it occurs at serine residues
78 and 82 by a specific kinase and may be activated by
several different signal transduction mechanisms.
Squamous tissues in several sites have been found to
strongly express the 27-Kda stress-response peptide in
suprabasal layers. 
A differential pattern of HSP27 "in vitro" expression
levels has been correlated to malignant transformation in
experimental models (La Thangue and Latchman, 1988).
Fibrosarcoma cells and breast cancer lines, transfected
with HSP27, exhibited delayed tumor progression and a
lower proliferation rate in comparison to controls
(Blackburn et al., 1997; Kindas-Mugge et al., 1998). On
the other hand HSP27 overexpression in malignant cells
obtained from a colon adenocarcinoma cell clone
increased their tumorigenicity in syngeneic animals
(Garrido et al., 1998). Breast cancer cell lines
overexpressing HSP27 displayed altered cell
morphology and decreased cell motility, as well as
enhanced proliferation (Lemieux et al., 1997).
Clinico-pathological and immunohistochemical
studies attempting to correlate the expression level of
HSP27 protein in tumor cells with tumor progression
and clinical outcome have also provided contradictory
results (Langdon et al., 1995; Storm et al., 1996; Hsu
and Hsu, 1998; Geisler et al., 1999; Vegh et al., 1999;
King et al., 2000). Therefore, it may be assumed that
there are wide variations in the degree of expression
between different cell types and tissues (Ciocca et al.,
1993b; Dunn et al., 1993).
In squamous cell carcinoma of the tongue no
correlation has been reported between HSP27 staining
and survival period, stage, lymph node metastasis or
histological grade (Ito et al., 1998). HSP27 expression
was markedly lower in Barrett 's metaplasia and
oesophageal adenocarcinomas than in normal mucosa,
but it was higher in oesophageal squamous cell
carcinomas (Soldes et al., 1999). Similarly Lambot et al.
(2000) observed an increased HSP27 protein expression
in malignant areas, from dysplastic lesions to invasive
carcinoma, being highest in the less differentiated areas.
On the other hand, Kawanishi et al. (1999) also reported
a reduced expression of HSP27 in patients with
esophageal squamous cell carcinoma (Kawanishi et al.,
1999) and therefore, they believed that HSP27 should be
considered an independent prognostic factor of this
disease (Kawanishi et al., 1999).
The frequency of squamous cell carcinoma of the
oral mucosa is rapidly increasing and, in particular, it
constitutes the most frequent malignant tumour of the
oral cavity. The incidence of metastasis depends on the
degree of cellular differentiation, degree of invasion and
site of the primary tumour. However, the clinical
behaviour of this tumour is difficult to predict based on
classical histopathological parameters alone. Biological
markers that can identify the lesions with an aggressive
phenotype and worse prognosis need to be identified. 
As it is well known, carcinogenesis is a multistage
process involving the activation of oncogenes and the
inactivation of tumour suppressor genes. In this context,
most human tumours are characterized by an imbalance
of regulatory mechanisms controlling cell-cycle
progression and/or the cell death/viability balance, or
apoptosis. 
Apoptosis has become a basic tool in developing
cancer research and establishing new cancer strategies.
Apoptosis, or programmed cell death, is a genetically
controlled process, which maintains developmental
morphogenesis (Vaux et al., 1994) and homeostasis of
differentiated organisms by removing senescent,
unneeded or dangerous cells (Sternberg, 1997).
Aberrations of this process leading to aberrantly reduced
cell death are thought to participate in cancer by
promoting increased resistance to therapy and favouring
the insurgence of transforming mutations (Jameson,
1998).
Considerable interest has recently been focused on
the identification of regulators of apoptosis, which may
potentially influence the cell death/cell viability balance
in cancer. In addition to pro- and anti-apoptotic bcl-2
molecules (Reed, 1998), and a second gene family of
Inhibitor of Apoptosis (IAP) (Crook et al., 1993), several
studies have recently focused on the role of HPSs in
human cancers.
To our kwnolegde only three studies on a few cases
examined HSP27 expression in oral squamous cell
carcinoma (Fortin et al., 2001; Leonardi et al., 2002;
Mese et al., 2002). In order to understand the biological
role of HSP27 in oral tumorigenesis, we studied HSP27
expression in oral cancers by immunohistochemistry and
western blot in samples of OSCCs and in oral cell lines,
correlating its expression with clinico-pathological
features 
Materials and methods
Selection of cases
The study population consisted of 57 men and 22
women with a mean age of 63,88 years (age range 20-
81). 35 cases were stage I, 20 stage II, 6 stage III, and 18
stage IV. All patients were analysed for survival rates
(the follow-up time was in all cases > 3 years). Survival
was calculated from the date of surgery to the date of the
latest clinical follow-up or death by disease. Patients
who died of postoperative complications were excluded
from the study. 
None of the patients had been treated previously.
They received surgical treatment with curative intention.
No patients had multicentric lesions.
Seventy-nine samples from paraffin-embedded and ten
from frozen specimens of primary oral squamous cell
carcinomas, and 7 from paraffin-embedded specimens of
lymph node and tissutal metastases of oral squamous cell
carcinomas (OSCCs) were used for the study. Specimens
were fixed in 10% neutral-buffered formalin. 
The histopathological grading was assessed on
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paraffin H&E - stained sections. Tumor extent was
classified according to the TNM system by UICC (Sobin
and Witterkind, 1997) and tumors were classified as
grade 1, 2 or 3, according the WHO classification of
histological differentiation. 
Ten paraffin-embedded and five frozen specimens of
healthy oral mucosa were obtained from patients who
had undergone routine oral surgical procedures, with the
informed consent of the donors. 
Immunohistochemistry
Four-µm serial sections from formalin-fixed,
paraffin-embedded blocks of representative areas 
of tumour were cut for each case. Only sections 
containing sufficient epithelium to assess the antibody
reactivity with 1000 cells were considered for this 
study.
Immunohistochemistry was then performed on the
remaining sections mounted on poly-L-lysine-coated
glass slides. Deparaffined and rehydrated sections were
incubated for 30 minutes in 3% H2O2/methanol to
quench endogenous peroxidase activity, and then rinsed
for 20 minutes with phosphate-buffered saline (PBS)
(Bio-Optica M107, Milan Italy). Non-specific protein
binding was attenuated by incubation for 30 minutes
with 5% horse serum in PBS. Specimens were incubated
overnight with the primary anti-HSP27 monoclonal
antibody (Catologue No. NCL-HSP27; Novocastra
Laboratories Ltd, Newcastle, U.K.) at a dilution of 1:20.
The antibody was applied directly to the section and the
slides were incubated overnight (4 °C) in a “humidified
chamber”. The sections were washed three times with
PBS at room temperature. Immune complexes were
subsequently treated with the secondary byotinilated
antibody and then detected by streptavidin peroxidase,
both incubated for 30 minutes at room temperature
(Vectastain ABC kit, Vector Laboratories, Burlingame,
CA, USA). After rinsing with 3 changes of PBS the
immunoreactivity was visualized by development for 2
minutes with 0,1% 3,3'-diaminobenzidine and 0,02%
hydrogen peroxide (DAB substrate kit, Vector
Laboratories Burlingame Calif.). Sections were
counterstained with Mayer's haematoxylin, mounted
with permanent mounting medium and examined by
light microscopy.
Positive controls consisted of tissue specimen
sections of breast carcinoma with known antigenic
reactivity. A negative control was performed in all cases
by substituting the primary antibody for normal rabbit
serum. Negative controls in all instances resulted in a
negative immunoreactivity for HSP27. To evaluate the
HSP27 expression, 300 cells were examined in at least
five areas at x400 magnification, and a mean percentage
of positive tumour cells was determined assigning cases
to one of the three following categories: a) positive (+),
when the stained cells accounted >80% of the total; b)
reduced (±), when the stained cells were comprised from
5 to 80% of the total cell population; and c) negative (-),
when the frequency of stained cells was <5%
(Kawanishi et al., 1999).
Western blot analysis
Two specimens of normal mucosa and five
cancerous specimens were used for western blot
analysis.
Proteins were extracted with T-Per Tissue (Pierce,
Rockford, IL) containing protease inhibitors (Sigma
Chemical Co., St. Louis, MO). The protein concentration
was determined by Bradford protein Assay (Sigma)
using BSA (Sigma) as a standard. Thirty µg of proteins
were solubilized in Laemmli’s sample buffer by boiling
for 8 min and subjected to 10% SDS-PAGE, followed by
electroblotting onto a nitrocellulose membrane (Bio-
Rad, Richmond, CA). The membrane was blocked for 1
hour at room temperature with PBS buffer containing
5% non-fat dry milk powder and 0.1% Tween 20.
Western blot analysis was performed using a monoclonal
antibody anti-HSP27 (Catalogue No. NCL-HSP27;
Novocastra Laboratories Ltd, Newcastle, U.K.) at a
dilution of 1:250 in PBS buffer containing 5% non-fat
dry milk powder and 0.1% Tween 20 for 60 min at room
temperature. Incubation with a secondary HRP-
conjugated goat antimouse antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) at dilution of 1:10000
was performed under the same conditions. For detection
of the immunocomplex, the SuperSignal West Pico
Chemiluminescent substrate (Pierce, Rockford, IL) was
used. Anti-beta-actin mouse monoclonal antibody (clone
AC-15; Sigma) was used for normalization of western
blot analysis.
Image analysis
Autographs obtained by western blot analysis were
subjected to densitometric analysis (Gel Doc 2000, Bio-
Rad, Richmond, CA) and the signal intensity of HSP27
and beta-actin was quantified. The mean values for
individual samples were normalised to the values for the
matching actin signal to compensate for any variation in
protein loading and concentration.
Statistical analysis
Data were analysed using GraphPad Prism software
version 3.00 for Windows (GraphPad Software, San
Diego California USA, www.graphpad.com). Significant
differences (P<0.05) between groups were determined
using one-way analysis of variance and the Student-
Newman-Keuls-test. Survival analysis was computed by
comparing positive (+), when the stained cells accounted
>80% of the total, reduced (±), when the stained cells
were comprised from 5 to 80% of the total cell
population, and negative (-), when the frequency of
stained cells was <5%. Survival curves were analyzed
according to the method of Kaplan-Meier and for
differences between curves the p value was calculated by
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the log-rank test. A p value of less than 0.05 was
accepted as statistically significant.
Results
Immunohistochemistry
HSP27 expression in normal oral mucosa 
Normal human oral mucous epithelium had a
suprabasal pattern of HSP27 expression (Fig. 1). The
labeling was cytoplasmic and finely granular with nuclei
very rarely showing only a faint staining and becoming
stronger from the parabasal layer to the surface layer.
Generally basal keratinocytes were not immunolabelled
by anti-HSP27 antibody, although a slight expression of
HSP27 was recorded in some areas. Thus, normal
epithelium included >80% of stained cells.
HSP27 expression in oral squamous cell carcinoma
Various staining patterns were observed for HSP27
expression in OSCCs (Fig. 1). Seven cases (7.5%)
showed <5% of positive tumor cells and were classified
as negative (-) (Table 1). In 48 cases (60.3%), the
positive tumor cells were comprised between 5 and 80%
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Table 1. Statistical analysis of HSP27 expression and associated clinico-pathological findings in oral SCCs.
VARIABLES No. SCORE - SCORE ± SCORE + MEAN STANDARD STANDARD p STATISTICAL DATA
n. (%) n. (%) n. (%) DEVIATION ERROR <0.05
Cases 79 7 (8.8) 48 (60.7) 24 (30.3)
Age
< 65 years 39 5 26 8 1.077 0.579 0.092 Yes° P = 0.0396
> 65 years 40 2 22 16 1.350 0.579 0.091
Sex
Male 57 6 34 17 1.193 0.610 0.080 No° P = 0.5948
Female 22 1 14 7 1.273 0.550 0.117
Grading Mean q P
Diff. value
G1 18 1 7 10 1.500 0.618 0.145 grade 3 vs grade1 -0,6176 4,723 < 0.01
G2 41 2 27 12 1.244 0.537 0.083 Yes* grade 3 vs grade 2 -0,3615 3,242 < 0.05
G3 20 4 14 2 0.900 0.552 0.123 grade 2 vs grade 1 -0,2561 2,343 > 0.05
Size
< 1.5 cm 27 4 32 9 1.185 0.681 0.131 No° P = 0.7478
> 1.5 cm 52 3 16 5 1.231 0.546 0.075
Lymph node metastasis
Negative 55 4 32 19 1.273 0.591 0.079 No° P = 0.1929
Positive (N+) 24 3 16 5 1.083 0.583 0.119
Staging Mean P
Difference value 
I 35 4 18 13 1.257 0.657 0.111 stage 4 vs stage 1 -0.1460 >0.05
II 20 0 15 5 1.250 0.444 0.099 No* stage 4 vs stage 2 -0.1389 >0.05
III 6 1 3 2 1.167 0.752 0.307 stage 4 vs stage 3 -0.05556 >0.05
IV 18 2 12 4 1.111 0.583 0.137 stage 3 vs stage 1 -0.09048 >0.05
stage 3 vs stage 2 -0.08333 >0.05
stage 2 vs stage 1 -0.007143 >0.05
Recidive
Yes 17 2 13 2 1.000 0.500 0.121 No° P = 0.1424
No 62 5 35 22 1.242 0.619 0.078
°:Student-Newmann-Keuls’ test. *:One-way Analysis of Variance (ANOVA) and Student-Newman-Keuls Multiple Comparisons Test. 
Fig. 1.a. Normal pattern of staining for HSP27 in oral epithelium, with a cytoplasmatic membrane localization in suprabasal layers (LSAB-AP, x 160). b.
Normal pattern of staining for HSP27 in oral epithelium at higher magnification in intermediate-superficial layers (LSAB-AP, x 250). c. OSCC 1 showing
intense cytoplasmatic signal for HSP27 (LSAB-AP, x 400).  d. A mosaic pattern with positive areas and negative areas HSP27 immunolabelling being
down-regulated in poorly-differentiated areas and up-regulated in highly-differentiated ones. (LSAB-AP,  x 250). e. Higher magnification: a mosaic
pattern with positive areas and negative areas HSP27 immunolabelling being down-regulated in poorly-differentiated areas and up-regulated in highly-
differentiated ones (LSAB-AP, x 400). f. Complete loss of immunostaining for HSP27 in a case of G2 OSCC, with sparse horn pearls exhibiting
cytoplasmatic localization of the signal (LSAB-AP, x 160). g. Complete loss of immunostaining for HSP27 in a case of G2 OSCC, with sparse horn
pearls exhibiting cytoplasmatic localization of the signal (LSAB-AP, x 160). h. Higher magnification: complete loss of immunostaining for HSP27 in a
case of G2 OSCC, with sparse horn pearls exhibiting cytoplasmatic localization of the signal and intense lymphoid infiltration (LSAB-HRP, x 250)
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1a 1b
1c 1d
1e 1f
1g 1h
and were evaluated as reduced (±) and in 24 cases
(30.7%), the positive tumor cells were >80% and were
evaluated as positive (+). In ± cases the pattern of
staining was not always homogeneous (diffuse decrease
in HSP27 expression); some cases, in fact, showed a
mosaic pattern (alternation of positive and negative
areas). So, in OSCC both low and high HSP27 levels of
expression could be appreciated HSP27
immunolabelling being down-regulated in poorly
differentiated areas and up-regulated in highly
differentiated ones. 
All cases of metastasis showed HSP27 positivity.
The frequency of lymph node metastases was higher in
HSP27-negative tumours (3/7, 42.8%) than in HSP-
reduced (16/48, 33.3%) or positive (5/26, 19.2%). 
Western blot and image analysis
HSP27 protein was expressed either in normal
mucosa or in cancerous samples to various extents.
Normal mucosa show lowed HSP27 expression, while
well differentiated oral carcinomas showed an HSP27
over-expression. Moderately- or poorly-differentiated
carcinomas had a reduced HSP27 expression (Fig. 2)
Densitometric analysis revealed relatively arbitrary
levels of expression which were, respectively: 5 and 23
in normal mucosa, 80 and 53 in well-differentiated
carcinomas, 28 and 17 in moderately-differentiated
carcinomas, and 3 in poorly-differentiated carcinoma.
HSP27 expression levels were relative to actin
expression.
Statistical analysis
There was no statistically significant correlation
between HSP27 expression, sex and tumour size, staging
or the presence of lymph node metastases (Table 1),
even if tumour without lymph node metastases had score
higher for HSP27 than tumour with metastases.
Regarding staging, low stages had a higher score than
high stages (stage I > stage II > stage III > stage IV).
Patients > 65 years had a higher score for HSP27.
HSP27 expression was reduced in poorly-differentiated
tumours, and these differences were statistically
significant (p < 0.05). When analysed for prognostic
significance, patients with negative/reduced HSP27
expression had poorer survival rates than the group with
positive HSP27 expression (Fig. 3). This difference in
survival rates was statistically significant (p < 0.05). 
Discussion
Among the several HSP proteins, HSP 27 and HSP
70 have been shown to have a strong association with
cancer, showing, during carcinogenesis, alteration of
their expression levels, either increasing or decreasing
(Ferrarini et al., 1992). 
Although HSP expression has been recognized as a
possible prognostic factor in some tumors, the data are
limited and often contradictory. Some studies reported
the reduced expression of HSP27 as a negative
prognostic factor in esophageal carcinoma (Kawanishi et
al., 1999), while others related its over-expression to
poor prognosis in astrocytoma (Hitotsumatsu et al.,
1996) and gastric carcinoma (Ciocca et al., 1993b) or to
increased tumor drug resistance in breast carcinoma
(Fuqua et al., 1994). Other studies reported no
significance of HSP27 expression in carcinomas of
prostate and bladder (Storm et al., 1993), and breast
(Tetu et al., 1995). 
HSP27 expression has been found absent in skin
cancers, particularly in poorly-differentiated areas, while
it has been shown in the supra-basal layers of normal
skin, and increased in all epithelial layers in
inflammatory skin lesions (Gandour-Edwards et al.,
1994; Trautinger et al., 1995b). HSP27 seems to play an
important role in keratinocytic tumorogenesis, by
delaying tumor development, as shown by experimental
studies (Kindas-Mugge and Trautinger., 1994). The data
concerning esophageal squamous cell carcinoma are
contradictory; one study correlated the over-expression
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Fig. 2. a. Expression levels of HSP27 in normal mucosa, lanes 1-2, and
in oral carcinomas, lanes 3-10. Lanes 3, 5: well-differentiated
carcinomas; lanes 6, 9: moderately-differentiated carcinomas; lane 10:
poorly-differentiated carcinoma. b. Expression of actin analysed as
control for sample loading, protein integrity and to normalize
densitometric analysis of HSP27 expression. 
a
b
Fig. 3. Survival analysis is computed by comparing negative (-)/reduced
(±) and positive (+) carcinomas for HSP27 staining. Patients with
negative/reduced score had poorer survival rates than patients with
positive staining. This difference in survival rates is statistically
significant (p<0.05). 
of HSP27 to poor histological differentiation (Lambot et
al., 2000), while other recent data suggested that the
expression of HSP27 is reduced in this carcinoma and
that this reduction is associated with poor postoperative
survival (Kawanishi et al., 1999). Probably the
discrepancy between these findings was due to a
different study population in the two studies: the first
study examined carcinoma occurring in smokers and/or
alcohol abusers, so these high levels of HSP27 can be
explained by the stress response of esophageal mucosa
to these irritant agents (Lambot et al., 2000).
A study on cancer of the tongue showed a positivity
for HSP27 in several cases (18/24) with no correlation
between HSP27 staining and survival, stage, lymph node
metastasis, histological grade or p53 immunostaining
(Ito et al., 1998). Similar data were obtained by another
study on head-neck carcinoma with HSP27 positivity in
86% of cases (43/50) without prognostic significance for
5-year survival (Gandour-Edwards et al., 1998). 
Other studies examined HSP27 expression in oral
carcinomas (Fortin et al., 2001; Leonardi et al., 2002;
Mese et al., 2002). Fortin examined 81 patients with oral
cavity and oropharyngeal carcinomas. 23% of HSP-27-
positive patients had neck failure compared with 51% of
HSP27-negative ones (p= 0.02). In a Cox model, HSP27
(p=0.05) was associated with neck failure and HSP27
expression may play a role in predicting nodal
failure(Fortin et al., 2001). Recently Mese et al. (2002)
examined 40 specimens of oral squamous cell carcinoma
for HSP27 expression by immunohisto-chemistry and
correlated with clinical stage, lymph node metastasis,
histological grade and survival period. HSP27 staining
was positive (+) in 20 (50%), weak or negative (-) in 20
(50%). There was no correlation between HSP27
expression and clinical stage, lymph node metastasis and
histological grade. However, when compared with
clinicopathological features, the expression of HSP27
correlated inversely with survival period. This study
suggests that the expression of HSP27 is frequently
promoted in patients with oral squamous cell carcinoma
and should be considered an independent prognostic
factor of OSCC. In our early study we showed no (5
cases, 29%) or low (8 cases, 46.4%) HSP27 staining in
oral premalignant lesions (Leonardi et al., 2002), while
in OSCC both low and high HSP27 levels of expression
were observed. HSP27 immunolabelling was down-
regulated in poorly differentiated areas and up-regulated
in highly differentiated ones. These findings indicated
that HSP27 expression seems to protect cells from
apoptosis during inflammation, while the down-
regulation in dysplasia could impair the protective
mechanism against mutagenesis induced by
environmental factors and thus enhancing the
transformation of oral epithelial dysplasia into OSCCs
(Leonardi et al., 2002). A study on OSCC lines showed
that recombinant clones overexpressing Hsp27 were
more resistant to IFN-gamma-induced cell death than
parent cells. Conversely, cells expressing a dominant-
negative mutant of Hsp27, in which three serine residues
(15, 78 and 82) were replaced by glycine, were
hypersensitive to the effects of IFN-gamma and
exhibited a typical apoptotic phenotype (Yonekura et al.,
2003). These data suggest that IFN-gamma suppresses
Hsp27 expression in oral SCC cells and blocks the
inhibitory effects of this molecular chaperone on
apoptotic cell death (Yonekura et al., 2003). Hsp27 plays
a crucial role in the inhibition of apoptosis of oral SCC
cells and Hsp27 plays a significant role in the IFN-
gamma-induced sensitization of oral SCC cells to
anticancer drugs (Yonekura et al., 2003). 
In this study the pattern of HSP27 protein expression
in oral mucosa, using immunohistochemistry, revealed
intense expression restricted to the suprabasal layer.
HSP27 was not present in the mitotic basal layer. Similar
data have been described in tongue epithelium (Ito et al.,
1998) and in the esophageal stratified squamous
epithelium (Soldes et al., 1999). This pattern of staining
suggests that the level of HSP27 may increase both with
the differentiation of oral epithelium or following
exposure to damaging agents. In epithelium of other
sites, such as cervical epithelium, in normal epidermis
and in skin neoplasms, HSP27 expression correlates to
the degree of cellular differentiation (Gandour-Edwards
et al., 1994; Trautinger et al., 1995c). Recent evidence
suggested that HSP27 is involved in the regulation of
epidermal differentiation (Jantschitsch et al., 1998) and
its absence in the upper epidermal layers may be a
marker for epidermal malignancy (Trautinger et al.,
1995b). 
Multiple studies have demonstrated the protective
effect of HSP27 protein against a wide variety of
cytotoxic stresses (Mehlen et al., 1995; Richards et al.,
1996a). Therefore, as has been suggested for esophageal
stratified squamous epithelium (Soldes et al., 1999), the
abundance of HSP27 in the oral mucosa may represent
one of the cellular mechanisms by which the oral
mucosa is protected against certain damaging agents.
The highest levels of HSP27 expression, with an
increase of immunoreaction products especially in the
basal layer, have been reported in some inflammatory
skin lesions (Gandour-Edwards et al., 1994; Trautinger
et al., 1995a), in esophagitis (Lambot et al., 2000) and
during wound healing (Laplante et al., 1998). Thus it is
reasonable to assume that HSP27 over-expression may
serve a protective function against the inflammatory-
stressful environment. In fact HSP27 protein has been
demonstrated to protect against a variety of
environmental stresses including heat shock, oxidative
injury, heavy metals, and tumor necrosis factor-alfa
(TNF-alfa) (Mehlen et al., 1995; Richards et al., 1996b;
Wu and Welsh, 1996). 
Moreover, HSP27 expression has been correlated to
malignant transformation of preneoplastic or potentially
malignant states in many body sites (Trautinger et al.,
1995c; Soldes et al., 1999; Lambot et al., 2000), even
though there are differences in the degree of HSP27
expression between cell types and tissues (Ciocca et al.,
1993a; Dunn et al., 1993).
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OSCCs showed positive levels of HSP27 staining,
especially in the highly differentiated area. This result is
consistent with in “vitro” findings that HSP27 gene
transfection within epidermal squamous cell lines
resulted in a lower proliferation rate (Kindas-Mugge et
al., 1996). The less differentiated area showed a reduced
expression of HSP27 or an absence of immunopositivity.
Our findings indicated that HSP27 expression is
altered in OSCC, where both low and high HSP27 levels
of expression could be appreciated, HSP27
immunolabelling being down-regulated in poorly-
differentiated areas and up-regulated in highly-
differentiated ones. Various staining patterns were
observed for HSP 27 expression in OSCCs. 55 cases
(70%) showed a reduction in HSP27 expression, while
24 cases (30%) showed no reduction. In reduced cases
the pattern was not always homogeneous with a diffuse
decrease in HSP27 expression, but some cases showed a
mosaic pattern with positive areas and negative areas.
There was a statistically significant positive correlation
between HSP27 expression and patient survival. When
analysed for prognostic significance, patients with
negative/reduced HSP27 expression had poorer survival
rates than the group with positive HSP27 expression and
this difference was statistically significant (p<0.05).
Western blot analysis, though performed in few
samples, confirmed the immunohistochemical results.
Patients with > 65 years showed higher score for
HSP27, because in these patients well differentiated
OSCC prevailed, while in < 65 years old patients low
differentiated were more numerous.
The function of this protein in tumor cells is still
unclear and remains controversial. Many studies have
reported a probable association between HSPs and cell
proliferation and the prevention of apoptosis helping
cells to survive, but this event appears strange in OSCCs
where the loss of HSP expression is associated with poor
prognosis. Differentiation is an important cellular
process that regulates the clonal expansion of the cell
population. Mehelen et al. (1997) reported that over-
expression of HSP27 is associated with reduced growth
of stem cells, not only with differentiation (Mehlen et
al., 1997). So high levels of HSP27 can be correlated
with well-differentiated tumours and with slow growth,
even if in some tumors high levels of HSP27 expression
were correlated with growth of poorly-differentiated
types and poor prognosis (Assimakopoulou et al., 1997).
Probably, the correlation between reduced expression
and poor survival can be explained by another HSP
function. The recent discovery of HSP families on the
surface of tumor cells, with an immunological
consequence, has suggested their possible role as tumor
antigens or tumor antigen carriers (Srivastava and Heike;
Srivastava, 1994; Srivastava et al., 1994). A study of
HSP expression in esophageal carcinomas showed
leukocyte infiltrations in tumoral areas expressing HSP,
possibly due to stimulation by some antitumor immunity
system (Kawanishi et al., 1999). Thus, patients with
HSP-positive tumors can be expected to have a better
prognosis.
Regarding other clinopathological data there was no
statistically significant correlation between HSP27
expression and sex, tumour size, staging or the presence
of lymph node metastases, even if tumour without lymph
node metastases had scored higher for HSP27 than
tumour with metastases. Frequency of lymph node
metastases was higher in HSP27-negative tumours (3/7,
42.8%) than in HSP-reduced (16/48, 33.3%) or positive
ones (5/26, 19.2%). With regard to staging, low stages
had higher scores than high stages (stage I > stage II >
stage III > stage IV). Conversely, the correlation
between HSP27 expression and grade was statistically
significant (p<0.05), showing reduced expression in
poorly-differentiated tumours and normal expression in
well-differentiated tumours.
So it seems that there is a relationship between
HSP27 expression and some clinical-histological
findings of oral cancer (grade and survival). Clearly
these results support the need for a larger study to verify
the possible role of HSP27 as a prognostic factor able to
identify patients at risk of more aggressive and
disseminated disease. This may be potentially relevant
for implementation of closer follow-up protocols and/or
alternative therapeutic regimens. 
In conclusion, these data suggest that HSP27
expression may be useful for the identification of cases
of oral squamous cell carcinoma with more aggressive
and invasive phenotype. Cases with reduced expression
were more aggressive and poorly differentiated, so
HSP27 expression seems to provide novel diagnostic
and prognostic information on individual patient survival
with oral cancers.
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